Phase 4 N=17 Bronchodilator Responsiveness in Obliterative Bronchiolitis
Obliterative Bronchiolitis
Primary: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators — 14; 7 per cent positive change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=26 Respiratory Impedance and Obliterative Bronchiolitis
Hematopoietic Stem Cell Transplantation · Obliterative Bronchiolitis
Primary: Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 0.07 1/cmH2O*s
Phase 2 N=25 Montelukast to Treat Bronchiolitis Obliterans
Bronchiolitis Obliterans · Chronic Graft Versus Host Disease · Leukotriene
Primary: Number of Participants With Stable or Improved Predicted Forced Expiratory Volume 1 (FEV-1) With Published Literature — 5; 7; 6; 1 Participants
Phase 2 N=36 Targeted Therapy of Bronchiolitis Obliterans Syndrome
Bronchiolitis Obliterans
Primary: Number of Subjects Who Failed Treatment — 2 Participants
Phase 4 N=83 Azithromycin in Bronchiolitis Obliterans Syndrome
Bronchiolitis Obliterans Syndrome · Graft Rejection · Lymphocytic Bronchiolitis
Primary: Prevalence of Bronchiolitis Obliterans Syndrome (BOS) — 5; 19 participants
Phase 2 N=7 Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans
Bronchiolitis Obliterans · Constructive Bronchiolitis · Graft Versus Host Disease
Primary: Improvement in Lung Function - Increase in FEV1 — 0 Participants
Phase 2 N=23 Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome
Constrictive Bronchiolitis · Bronchiolitis Obliterans · Graft vs Host Disease
Primary: Overall Response to Treatment Based on Positive Response to Cyclosporine Inhalation Solution (CIS) — 9; 0 Participants
Phase 4 N=30 Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)
Complication of Transplanted Lung
Primary: Change in Pulmonary Function, as Measured by Serial Forced Expiratory Volume in 1 Second (FEV1) on Spirometry — -0.04 Liter — p=0.2030
Phase 2 N=10 Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
Restrictive Chronic Lung Allograft Dysfunction · Lung Transplant Rejection
Primary: Tolerability of Pirfenidone — 3 Participants
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
N/A N=161 Intermittent Versus Continuous Pulse Oximetry Monitoring of Infants Admitted for Bronchiolitis
Bronchiolitis · Hypoxia
Primary: Length of Stay in the Hospital — 38.7; 39.5 hours — p=<0.05
N/A N=28 Prophylactic Bronchoscopy After Inhalation Injury in Burn Patients
Inhalation Injury · Pneumonitis · Pneumonia
Primary: All Cause Mortality — 0; 1 participants
Phase 2 N=40 Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
Plastic Bronchitis · Protein-Losing Enteropathies · Healthy
Primary: Primary Endpoint: Number of Subjects That Develop New, Active Bleeding — 0 Participants
N/A N=49 Physiology of Lung Collapse Under One-Lung Ventilation: Underlying Mechanisms
Lung Collapse · One-Lung Ventilation · Thoracic Surgery
Primary: Quantification of Gas Volume Coming From Ambient Air Towards the Alveoli Space of the Non-ventilated Lung During OLV With the Use of DLT and BB. — 504; 630 milliliters…
N/A N=256 Analysis of BPD in Premature Infants With Typical Imaging Changes
Bronchopulmonary Dysplasia
Primary: Mortality — 17; 7 Participants
Phase 2 N=88 Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
Respiratory Distress Syndrome in Premature Infant · Bronchopulmonary Dysplasia
Primary: Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 12 Months Corrected Gestational Age (CGA) — 8; 2; 6; 6 Number of events
N/A N=304 The Bronchiolitis Follow-up Intervention Trial
Bronchiolitis
Primary: Parental Anxiety — 4.2; 3.9 points on a scale
Phase 2 N=21 Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients
Disorder Related to Lung Transplantation · Bronchiolitis Obliterans · Decreased Immunologic Activity
Primary: Number Of Participants With Chronic Rejection Who Met Primary Combined End-point — 2; 5 Participants — p=0.03
N/A N=40 Lung Collapse With Bronchial Blocker
Video-assisted Thoracoscopic Surgery · Lung Isolation Device · One-lung Ventilation
Primary: Time to Obtain Complete Lung Collapse — 47.8; 32.5 minutes
Phase 2 N=5 Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant
Primary Immunodeficiency · PID
Primary: Safety: Death — 4 Participants
N/A N=204 OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study
Idiopathic Pulmonary Fibrosis
Primary: Idiopathic Pulmonary Fibrosis (IPF)-Related Costs — 38923.57; 22613.68; 20369.94; 37183.17 Euro (€) — p=0.0002
Phase 3 N=62 Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)
Bronchiolitis Obliterans · Chronic Rejection of Lung Transplant · Lung Transplant Rejection
Primary: Mean Change in FEV1 (L) From Baseline to Week 48 — -0.186; -0.090 liters — p=0.7310
N/A N=49 FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
N/A N=1,283 Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Post-bronchodilator FEV1/FVC <=70% Versus Participants With a Postbronchodilator FEV1/FVC >70% — 308; 893 participants
N/A N=228 Bronchiolitis Recovery and the Use of High Efficiency Particulate Air (HEPA) Filters
Bronchiolitis
Primary: Number of Caregiver-reported Symptom-free Days (SFDs) — 118.01; 112.60 Days — p=0.537
Phase 4 N=196 Prevention of OM-85 on Bronchiectasis Exacerbation
Bronchiectasis With Acute Exacerbation
Primary: Bronchiectasis Exacerbation — 0.98; 0.75 proportion of acute exacerbations
Phase 3 N=169 Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
Bronchiolitis Obliterans · Chronic Rejection of Lung Transplant · Lung Transplant Rejection
Primary: Mean Change in FEV1 (Liters) From Baseline to Week 48 — -0.096; -0.067 Liters — p=0.6639
N/A N=103 The Effectiveness of AAD and IPV to Treat Hospitalized Infants (<2years) With Acute Viral Bronchiolitis.
Bronchiolitis
Primary: Length of Hospital Stay — 3.5; 3.6; 4.5 days
N/A N=270 Comparison of Classification Standards of Bronchopulmonary Dysplasia (BPD) in Premature Infants
Bronchopulmonary Dysplasia
Primary: Respiratory Adverse Outcomes — 27; 60 Participants
Phase 2 N=16 Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients
Lung Transplant Infection
Primary: Number of Participants Free From New or Progressive Chronic Lung Allograft Dysfunction — 2; 4 Participants